Idera holds out hope for IMO-2055 after negative Phase II head and neck cancer data
This article was originally published in Scrip
Executive Summary
Undeterred by topline results from a Phase II clinical trial which did not meet the primary endpoint Idera Pharmaceuticals still believes it can find ways to make its oncology drug candidate IMO-2055 work. When given in combination with ImClone's Erbitux (cetuximab) to treat recurrent or metastatic squamous cell carcinoma of the head and neck, progression-free survival did not improve.
You may also be interested in...
Finance Watch: Biopharma VC Explosion Extends To Tools, Services
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Amgen Hands Omecamtiv Back To Cytokinetics
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Need a specific report? 1000+ reports available
Buy Reports